



ADMINISTRATIVE POLICY STATEMENT

Georgia Medicaid

Policy Name & Number	Date Effective
Pharmacogenomics-CYP Gene Testing-GA MCD-AD	

Table of Contents

A. Subject	2
B. Background	2
C. Definitions.....	2
D. Policy	2
E.	
G. Review/Revision History	4
H. References	4

A. Subject

Pharmacogenomics- CYP Gene Testing

B. Background

Pharmacogenomics is an area of precision medicine that provides information about an

benefit or toxicity to a given drug. This form of medication management has been evaluated in a variety of clinical scenarios. As pharmacogenomics expands and laboratories offering testing proliferate, the value of a given test in terms of patient benefit may be obscured by multiple contributing factors, including exaggerated public marketing claims, inconsistencies in test standardization, continued patient variation in response to prescribed medication, incomplete knowledge of drug metabolism, and limitations in regulatory oversight. To manage these challenges, the clinical validity and clinical utility of a specific gene or biomarker with a specific drug target should demonstrate improvement in patient outcomes.

C. Definitions

- **Clinical Utility** The likelihood that a test will, by prompting an intervention, result in an improved health outcome.
- **Clinical Validity** The accuracy of a test for a given clinical outcome.
- **Unbundling** HCPCS/CPT codes should be reported only if all servBT/F1 9f1 ervBT[(g)] TJETQqC

11. Clinical Utility Evaluation: MTHRF Genetic Testing for Nondevelopmental Psychiatric Disorders. Hayes; 2023. Accessed March 14, 2024. www.hayesinc.com
12. Clinical Utility Evaluation: MTHRF Genetic Testing for Pregnancy Complications. Hayes; 2023. Accessed March 14, 2024. www.hayesinc.com
13. Clinical Utility Evaluation: MTHRF Genetic Testing for Severe MTHFR Enzyme Deficiency. Hayes; 2023. Accessed March 14, 2024. www.hayesinc.com
14. Clinical Utility Evaluation: MTHRF Pharmacogenetic Genotyping for Altering Drug Treatment. Hayes; 2017. Updated May 23, 2021. Accessed March 14, 2024. www.hayesinc.com
15. Clinical Utility Evaluation: Pharmacogenetic and Pharmacogenomic Testing for Opioid Treatment for Pain in Adults Selected Single-Gene Variants and Pharmacogenomic Panels. Hayes; 2019. Updated October 26, 2022. Accessed March 14, 2024. www.evidenced.hayesinc.com
16. Clinical Utility Evaluation: Pharmacogenetic and Pharmacogenomic Testing to Improve Outcomes Related to Opioid Use Disorder. Hayes; 2020. Updated June 30, 2023. Accessed March 14, 2024. www.evidence.hayesinc.comnc.com

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.

